Glaxo sells international non-core OTC brands to Aspen

GlaxoSmithKline's shareholders are set for another return of capital this year following the divestment of more non-core over-the-counter (OTC) brands in its international markets to Aspen Pharmacare Holdings.

GlaxoSmithKline's shareholders are set for another return of capital this year following the divestment of more non-core over-the-counter (OTC) brands in its international markets to Aspen Pharmacare Holdings.

The company announced on Friday afternoon that it will sell 'Phillips MOM', 'Solpadeine', 'Dequadin', 'Cartia' and 'Zantac' to Aspen for £163m. These brands generated sales of around £60m in 2011, the company said. Net profit on this disposal in 2012 is £105m before tax (after deducting transaction costs and a profit deferral of approximately £25m pre-tax arising because Aspen is an associate of GSK.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up
Latest Videos FromMoneyWeek
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.